Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This multicenter, prospective Phase I study is aimed at testing the safety of F8IL10 via i.a.
administration once every 4 weeks over 8 weeks in patients with RA who, despite treatment
with stable doses (at least 3 months) of DMARDs (conventional, biologic and/or targeted
synthetic), present arthritis flare(s) suitable for i.a. injections.